*Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA; and
†Division of Cardiovascular Medicine, Harvard Medical School, Boston, MA.
Reprints: Leo F. Buckley, PharmD, Department of Pharmacy Services, Brigham and Women's Hospital, 75 Francis St, PB-AB-314, Boston, MA 02120 (e-mail: [email protected]).
P. Libby is supported by the National Heart, Lung, and Blood Institute: (R01HL080472); American Heart Association (18CSA34080399); RRM Charitable Fund.
P. Libby is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron, and XBiotech, Inc. P. Libby is a member of scientific advisory board for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, IFM Therapeutics, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, and XBiotech, Inc. P. Libby's laboratory has received research funding in the last 2 years from Novartis. The remaining author reports no conflicts of interest.
